Transpire Bio Gains FDA Acceptance for High-Strength Generic Trelegy
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SUNRISE, Fla., May 11, 2026 Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...
WESTON, FLORIDA, April 27, 2026 Apotex has secured U.S. Food and Drug Administration (FDA) approval for its generic Infuvite®...
MIRAMAR, Fla., April 9, 2026 DifGen Pharmaceuticals LLC, in collaboration with Apotex Inc., has announced that the U.S. Food...
MUMBAI, India and WARREN, N.J., April 3, 2026 Cipla USA Inc., a subsidiary of Cipla Limited, has received final...
MUMBAI, India & NAPLES, Fla., USA, March 31, 2026 Lupin Limited has received tentative approval from the U.S. Food...
MUMBAI, INDIA & NAPLES, USA | March 25, 2026 Lupin Limited, a global pharmaceutical leader, has received tentative approval...
February 24, 2026 – Pittsburgh, Pennsylvania, USA Consegna Pharma, Inc. has announced that the U.S. Food and Drug Administration...
February 24, 2026 – Mumbai, India & Naples, Florida, USA Global pharmaceutical leader Lupin Limited has announced that it...
